HC Wainwright Issues Pessimistic Forecast for RMTI Earnings

Rockwell Medical, Inc. (NASDAQ:RMTI) – HC Wainwright decreased their FY2026 earnings per share estimates for Rockwell Medical in a report released on Monday, May 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.08) for the year, down from their prior estimate of ($0.05). HC Wainwright currently has a “Buy” rating and a $2.00 target price on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.05) per share.

Other equities research analysts have also issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rockwell Medical in a research note on Tuesday, April 21st. Wall Street Zen upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $2.00.

Rockwell Medical Price Performance

RMTI stock opened at $0.84 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 3.63 and a current ratio of 3.74. Rockwell Medical has a 1 year low of $0.74 and a 1 year high of $2.10. The firm has a market cap of $33.28 million, a P/E ratio of -5.62 and a beta of 1.65. The stock has a 50-day simple moving average of $0.91 and a 200-day simple moving average of $0.96.

Rockwell Medical (NASDAQ:RMTI) last posted its earnings results on Thursday, May 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03). Rockwell Medical had a negative net margin of 7.98% and a negative return on equity of 15.41%. The company had revenue of $17.34 million during the quarter, compared to analyst estimates of $17.95 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd boosted its holdings in Rockwell Medical by 286.5% in the fourth quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after purchasing an additional 46,029 shares during the last quarter. Jane Street Group LLC purchased a new position in Rockwell Medical in the fourth quarter valued at about $84,000. GSA Capital Partners LLP boosted its holdings in Rockwell Medical by 635.1% in the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock valued at $197,000 after purchasing an additional 141,672 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Rockwell Medical by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after purchasing an additional 41,668 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Rockwell Medical by 12.3% in the third quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock valued at $1,625,000 after purchasing an additional 148,737 shares during the last quarter. Hedge funds and other institutional investors own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.